(NASDAQ: LTRN) Lantern Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.35%.
Lantern Pharma's earnings in 2026 is -$18,652,935.On average, 3 Wall Street analysts forecast LTRN's earnings for 2026 to be -$21,254,921, with the lowest LTRN earnings forecast at -$20,421,395, and the highest LTRN earnings forecast at -$21,880,066. On average, 3 Wall Street analysts forecast LTRN's earnings for 2027 to be -$26,340,454, with the lowest LTRN earnings forecast at -$25,307,495, and the highest LTRN earnings forecast at -$27,115,174.
In 2028, LTRN is forecast to generate -$27,514,039 in earnings, with the lowest earnings forecast at -$26,435,057 and the highest earnings forecast at -$28,323,275.